Our data suggest that SHP2 may play a unique role in modulating ERK pathway activation in CCDC6-RET–rearranged thyroid cancer cells, and that pSHP2 and pSTAT3 may be biomarkers of adaptive resistance to RET inhibition. This evidence concerns the gene CCDC6 and thyroid gland carcinoma.